Welcome to the ATTD 2023 Interactive Program

Abstract Body

Therapeutic insulin is lifesaving for many people with diabetes. However, despite 100 years of experience and many innovations, its use is still associated with elevated risks of hypoglycaemia, the burden of which impacts considerably on many aspects of daily life with diabetes. Hypoglycaemia remains a major barrier to achieving optimal glucose control, reduces quality of life, increases health care demand and costs, and is associated with cardiovascular events, cognitive decline and death. The Hypoglycaemia REdefining SOLutions for better liVEs (Hypo-RESOLVE) project is a public-private partnership that aims to increase our understanding of hypoglycaemia through a comprehensive multilevel approach in order to reduce the burden of hypoglycaemia. One of the activities is the construction of the Hypo-RESOLVE database, which contains data on hypoglycaemia from 98 clinical trials on insulin treatment among 60,000 participants with type 1 or type 2 diabetes, analysis of which will reveal better insight into the consequences of and risk factors for different levels of hypoglycaemia. In addition, the embedded 10-week Hypo-METRICS study will examine the psychological, clinical and health-economic impact of sensor-detected low interstitial glucose values and its relevance as compared to patient-reported hypoglycaemia. A large hypoglycaemic glucose clamp study, conducted among over 100 people with type 1 or type 2 diabetes, aims to reveal potential mechanisms underlying the association between hypoglycaemia and cardiovascular disease, focussing on inflammatory parameters and cardiac function. Qualitative research and a quantitative survey examine the widespread impact of hypoglycaemia on various aspects of quality of life, diabetes distress and related aspects in people with or affected by diabetes Finally, the basic science component of the project will reveal novel pathways of hypoglycaemia sensing, so as to better understand the pathophysiology of impaired awareness of hypoglycaemia. Data from Hypo-RESOLVE will provide the evidence needed to solidify the current and widely adopted International Hypoglycaemia Study Group (IHSG) 3-level classification of hypoglycaemia. Collectively, the outcomes of Hypo-RESOLVE will advance our understanding of hypoglycaemia, so as to alleviate its burden and improve the lives of people with diabetes.